Tuberculosis remains the world’s leading infectious disease killer, claiming 4,500 lives each day. Every year, some 558,000 people will develop a form of TB that is resistant to rifampicin, the most effective first-line drug, making successful treatment of the disease even more difficult and costly.
Ending the global epidemic requires a comprehensive approach, rapid innovation and proven interventions, bold leadership, and intensive community engagement.
